Turnstone Biologics shares are trading higher after B of A Securities initiated coverage on the stock with a Buy rating and $18 price target.
Portfolio Pulse from Benzinga Newsdesk
Bank of America Securities has initiated coverage on Turnstone Biologics with a Buy rating and a price target of $18. This has led to an increase in the trading of Turnstone Biologics shares.
August 15, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Turnstone Biologics' stock is trading higher following a Buy rating and $18 price target from Bank of America Securities.
The initiation of coverage by a major financial institution like Bank of America Securities often leads to increased investor interest. The Buy rating and the price target of $18, which is presumably higher than the current trading price, suggest a positive outlook for the stock. This is likely to lead to increased buying activity, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100